The trial was designed to assess the efficacy and safety of semaglutide, a once-weekly subcutaneous glucagon-like peptide 1 (GLP-1) receptor agonist, in preventing major kidney outcomes, specifically kidney failure, substantial loss of kidney function, and death from kidney or cardiovascular causes, in individuals with type 2 diabetes and chronic kidney disease
Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial
Its the first medication in a class called dual GIP/GLP-1 agonists
Understanding how semaglutide affects sleep can help you know what to expect and how to manage any changes safely
While taking a Semaglutide diet shot for weight loss, focus on a balanced diet to support your goals
Waziry, R